# Neuropsychiatric Phenotype and Treatment Challenges in 47,XYY Syndrome: A Narrative Review with a Case Series of Adolescents

## TL;DR

47,XYY syndrome is linked to a range of neuropsychiatric issues, including ADHD and mood disorders, with treatment challenges emerging in adolescence.

## Contribution

This paper provides a narrative review and case series highlighting the progression of neuropsychiatric symptoms and treatment resistance in adolescents with 47,XYY syndrome.

## Key findings

- 47,XYY syndrome is associated with increased risks of language impairment, ADHD, and autism spectrum traits.
- Adolescents with 47,XYY syndrome show higher rates of mood and psychotic disorders, suggesting increased psychiatric vulnerability.
- A subset of adolescents exhibits progressive behavioral dysregulation and limited response to psychotropic medications.

## Abstract

What are the main findings?
47,XYY syndrome is associated with a broad and heterogeneous neuropsychiatric phenotype.Increased risks include language impairment, executive dysfunction, ADHD and autism spectrum traits.

47,XYY syndrome is associated with a broad and heterogeneous neuropsychiatric phenotype.

Increased risks include language impairment, executive dysfunction, ADHD and autism spectrum traits.

What are the implications of the main findings?
Psychiatric vulnerability appears to rise during adolescence, with higher rates of mood and psychotic disor-ders.Case series findings suggest progressive behavioral dysregulation and possible pharmacoresistance in a sub-set of adolescents.Long-term, multidisciplinary monitoring is essential to improve clinical outcomes.

Psychiatric vulnerability appears to rise during adolescence, with higher rates of mood and psychotic disor-ders.

Case series findings suggest progressive behavioral dysregulation and possible pharmacoresistance in a sub-set of adolescents.

Long-term, multidisciplinary monitoring is essential to improve clinical outcomes.

Background: 47,XYY syndrome is a relatively common sex chromosome aneuploidy that remains largely underdiagnosed. While its somatic phenotype is often mild, growing evidence indicates a substantial burden of neurodevelopmental and psychiatric morbidity. However, the characterization of the neuropsychiatric phenotype across development, particularly during adolescence, and the associated treatment challenges remain incomplete. Objectives: To provide a comprehensive narrative review of the neuropsychiatric phenotype of 47,XYY syndrome and to illustrate clinical complexity and treatment response through a case series of adolescents. Methods: A narrative review of the literature was conducted focusing on genetics, neurodevelopmental and psychiatric features, neuroimaging and neurophysiology findings, clinical course, and management strategies in 47,XYY syndrome. This review is complemented by a case series of adolescents with confirmed 47,XYY karyotype, evaluated for developmental history, psychiatric comorbidity and response to pharmacological and non-pharmacological interventions. Results: The literature consistently describes increased risks of language impairment, executive dysfunction, ADHD, autism spectrum traits, and emotional and behavioral dysregulation in males with 47,XYY syndrome. Psychiatric vulnerability appears to increase during adolescence and adulthood, with elevated rates of mood, psychotic, and substance use disorders. The presented cases illustrate a convergent clinical trajectory marked by early developmental delays, progressive behavioral dysregulation in adolescence and limited or inconsistent response to multiple classes of psychotropic medications, suggesting a pattern of pharmacoresistance in a subset of patients. Conclusions: 47,XYY syndrome is associated with a distinct and heterogeneous neuropsychiatric phenotype that extends beyond early neurodevelopmental disorders. Early diagnosis alone may be insufficient to prevent severe psychiatric outcomes, highlighting the need for long-term monitoring and integrated, multidisciplinary management. Further research is required to identify early predictors of high-risk trajectories and to optimize treatment strategies for this population.